Currently, talimogene laherparepvec (T-VEC), a herpes simplex virus-1 (HSV) engineered to express the cytokine gene granulocyte-macrophage colony-stimulating factor (GM-CSF), is the only oncolytic virus approved for cancer therapy [82, 83]. Here, CSF2 is linked to cancer.